Evidence map›Paper›PMID 30713473›Full record

ArticleEXCLI journal2018

Cyclosporin A attenuating morphine tolerance through inhibiting NO/ERK signaling pathway in human glioblastoma cell line: the involvement of calcineurin.

Asma Rashki, Faiza Mumtaz, Farahnaz Jazayeri, Amir Shadboorestan, Jamileh Esmaeili, Shahram Ejtemaei Mehr, Mohammad Hossein Ghahremani, Ahmad Reza Dehpour

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Furanoditerpenes fromACS chemical neuroscience · 2022
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Asma RashkiExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Faiza MumtazExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Farahnaz JazayeriDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir ShadboorestanDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Jamileh EsmaeiliDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shahram Ejtemaei MehrDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein GhahremaniDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad Reza DehpourExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclosporin A (CsA) is known to have an immunosuppressive action. However, it is also attracting attention due to its effects on the nervous system, such as inhibiting the development and expression of morphine-induced tolerance and dependence through unknown mechanisms. It has been shown that CsA modulates the nitric oxide (NO) synthesis and extracellular signal-regulated kinases (ERK) activation, which are potentially involved in signaling pathways in morphine-induced tolerance in cellular models. Therefore, the current study was designed to evaluate the modulatory role of CsA on the MOR tolerance, by targeting the downstream signaling pathway of NO and ERK using an

Indexed as

Cyclosporin Aextracellular signal-regulated kinasesmorphinenitric oxideT98G cellstolerance

Identifiers

PMID30713473
PMCPMC6341459
OpenAlexW2945171564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.